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Experimental Procedures 
Generation of plasmid pTUC202 RGD by site-directed mutagenesis. Plasmid pTUC202 carrying the 
MccJ25 biosynthetic gene cluster was used as the template for site-directed mutagenesis.[1]
RGD_FP 5’ - GCAGGACATGTGCCTGAGTATTTTGTG
 
Mutagenesis was performed using Phusion High-Fidelity DNA-Polymerase (New England Biolabs) in 
the presence of 8% DMSO and the RGD sequence was inserted into the microcin J25 precursor gene 
mcjA by the following pair of primers:  
CGGGGTGATACACCTATATCTTTCTATGGCTG - 3‘ 
RGD_RP 5‘ - CAGCCATAGAAAGATATAGGTGTATCACCCCGCACAAAATACTCAGGCACATGTCCTGC - 3‘. 
Mutagenized plasmid DNA was transformed into chemically competent Escherichia coli NEB 10-beta 
cells (New England Biolabs). Transformed cells were plated on LB agar plates containing 34 µg mL-1
 
 
chloramphenicol and incubated overnight at 37 °C. Plasmids were prepared from individual 
transformants and analyzed via restriction mapping and subsequent DNA dideoxy sequencing (GATC 
Biotech). 
Heterologous production of MccJ25 and MccJ25 RGD. Heterologous production of MccJ25 and the 
grafted analog MccJ25 RGD was performed as described previously.[2] In brief, transformants of 
Escherichia coli DH5α harboring the pTUC202 or pTUC202 RGD plasmid were cultured for 24 h at 37 
°C in 500 mL M63 medium in 2 L baffled flasks containing 2 µg mL-1 thiamine/biotin, 0.2% glucose and 
34 µg mL-1
 
 chloramphenicol.  
Extraction and purification of MccJ25 and MccJ25 RGD. The culture supernatant of a 5 L 
fermentation of E. coli DH5α [pTUC202] or E. coli DH5α [pTUC202 RGD] was obtained by 
centrifugation for 45 min at 4 °C at 6000 rpm. Afterwards the culture supernatant was applied to 
solid phase extraction using ~ 5 g XAD16 resin (Sigma-Aldrich) per liter of supernatant. After 
incubation of the culture supernatant with XAD16 resin for 30 min the supernatant was removed by 
filtration and the resin was washed with 300 mL water and eluted with 300 mL methanol. The 
methanol eluate was evaporated to dryness and dissolved in 10 mL 20% methanol. 2.5 mL of the 
prepared extract were filtered using a 0.45 µm filter and applied onto a RP-HPLC preparative 
Nucleodur C18ec column (250 mm × 21 mm). In the case of MccJ25 RGD, elution was performed by 
applying the following gradient of water/0.1% TFA (solvent A) and methanol/0.1% TFA (solvent B) at 
a flow rate of 18 mL min−1: linear increase from 40% to 55% B within 30 min followed by a linear 
increase from 55% to 95% B within 5 min followed by holding 95% B for 1 min. The retention time of 
MccJ25 RGD was 28.7 min. The grafted lasso peptide could be purified to homogeneity using the 
aforementioned two step protocol from the culture supernatant with a yield of 0.7 mg L-1
 
. In the case 
of MccJ25, the first linear gradient increased from 60% to 70% B within 30 min. The retention time of 
the wild type peptide was 29.3 min and 1 mg could be purified from 1 L of the culture supernatant.  
Carboxypeptidase Y digestion assays of MccJ25 RGD. 10 – 20 µg of purified MccJ25 RGD or wild type 
lasso peptide were incubated in a 50 µL reaction in 20 mM Tris/HCl, pH 8.0, in the presence of 0.01 – 
1 U carboxypeptidase Y for 15 – 120 min at 25 °C. Subsequently the assay was stopped by heat 
inactivation of the protease for 5 min at 95 °C. Afterwards the assays were analyzed via HPLC-HRMS 
using a Nucleodur 125/2 C18ec column applying the following gradient of water/0.05% formic acid 
(solvent A) and acetonitrile/0.045% formic acid (solvent B) at a column temperature of 40 °C and a 
flow rate of 0.2 mL min-1: Linear increase from 10% to 95% B with 35 min followed by holding 95% B 
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for 2 min. MccJ25 RGD showed a retention time of 16.1 min, whereas the wild type lasso peptide 
eluted at 17.8 min. 
 
Stability studies of MccJ25 RGD and the linear heptapeptide P1 in human serum. The enzymatic 
degradation was studied using male human serum type AB (Aldrich) and Hanksʼ Balanced Salt 
solution (HBSS) (Aldrich). The peptides were dissolved in a serum-HBBS solution (9:1) at a 
concentration of 2 mg mL-1
 
 and incubated at 37 °C. 50 µL aliquots were periodically taken at different 
time points and poured into 200 µL of cold methanol to precipitate the proteins and stop the 
degradation process. Samples were cooled on ice for 30 min and next centrifuged at 10000 rpm for 
15 min at 4 °C. Since the peptides were completely soluble in methanol, the supernatant was 
analyzed by HPLC. 
Mass spectrometric analysis of MccJ25 and MccJ25 RGD. The mass spectrometric characterization 
of the grafted lasso peptide MccJ25 RGD and the wild type peptide MccJ25 was performed with an 
LTQ-FT instrument (Thermo Fisher Scientific, Germany) connected to a microbore 1100 HPLC system 
(Agilent, Germany). Separation of MccJ25 RGD and MccJ25 from contaminants was achieved using a 
125/2 Nucleodur C18ec column (Macherey-Nagel, Germany). Following gradient of water/0.05% 
formic acid (solvent A) and acetonitrile/0.045% formic acid (solvent B) was applied at a column 
temperature of 40 °C and a flow rate of 0.2 mL min−1
CID fragmentation studies within the linear ion trap were performed with purified lasso peptide 
samples, which were analyzed using a syringe pump at a flow rate of 10 μL min
: linear increase from 10% to 95% B within 35 
min followed by holding 95% B for 2 min.  
−1
 
. Usually, the doubly 
charged ions were selected for fragmentation in the ion trap applying normalized collision energy of 
35. 
NMR spectroscopic analysis of MccJ25 RGD. Sample for NMR measurements contained 7.2 mg of 
MccJ25 RGD in 280 µL of CD3OH at 298 K. Spectra were recorded on a Bruker Avance 600 MHz 
spectrometer equipped with an inverse probe with z-gradient. Samples were filled into Wilmad 3mm 
tubes obtained from Rototec Spintec. Temperature effect on the structure was surveyed by 
recording 1H spectra at variable temperatures. 1H and TOCSY spectra were recorded in CD3OD at 298 
K sequentially 0.5 h, 2 h, 24 h and 4 weeks after sample preparation. For sequential assignment, DQF-
COSY, TOCSY, and NOESY experiments were performed in phase-sensitive mode using States-TPPI.[3-6] 
TOCSY spectra were recorded with mixing time of 80 ms. NOESY spectra were taken at 100 and 250 
ms mixing times. Solvent suppression was fulfilled by using excitation sculpting with gradients for 
DQF-COSY, TOCSY, and NOESY experiments.[7] 1D spectra were acquired with 65 536 data points, 
while 2D spectra were collected using 4096 points in the F2 dimension and 512 increments in the F1 
dimension. For 2D spectra 32 transients were used. Relaxation delay was 2.5 s. Chemical shifts were 
referenced to solvent signal. All spectra were processed with Bruker TOPSPIN 2.1. NOE cross-peaks 
were analyzed within the program Sparky.[8]
 
 
Synthesis of Ac-Phe-Val-Arg-Gly-Asp-Thr-Pro-NH2 (P1). The peptide was manually synthesized in 
solid-phase using the Fmoc strategy. Solvents and soluble reagents were removed by suction. 
Washings between deprotection, couplings, and subsequent deprotection steps were carried out 
with NMP and CH2Cl2, using 10 mL of solvent/g of resin each time. The Fmoc group was removed by 
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treatment with piperidine−NMP (1:4, v/v) for 2 x 10 min. Couplings and washes were performed at 
25 °C. Couplings were monitored using Kaiser or chloranil methods.[9]
Fmoc-Rink Amide MBHA resin (200 mg, 0.65 mmol g
 
-1) was placed in a 10 mL-polypropylene syringe 
fitted with a polyethylene filter disk. After Fmoc removal, Fmoc-amino acids (3 equiv) were coupled 
with TBTU (3 equiv), HOBt (3 equiv) and DIEA (6 equiv) in NMP for 2 h. Alternatively, couplings were 
performed using HATU (3 equiv), HOAt (3 equiv) and DIEA (6 equiv) in NMP for 1 h. Side chains of 
Fmoc-amino acids were protected as follows: Thr and Asp were protected with the tert-butyl group 
(tBu) and Arg with the 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl group (Pbf). The peptide 
was finally N-acetylated with Ac2O−DIEA−NMP (1:2:7) for 30 min. For the deprotection of side-chain 
groups and concomitant cleavage of the peptide from the support, the resin was washed with CH2Cl2 
(3 x 1 min), dried, and treated with TFA−H2O−TIS (95:2.5:2.5) for 1.5 h. TFA was then removed by 
evaporation with nitrogen, and the peptide was precipitated with cold diethylether, dissolved in 
H2O−MeCN (1:1) and then lyophilized. The crude peptide was purified by semi-preparative HPLC 
(from 10 to 50 % MeCN over 20 min, flow rate 8 mL min-1). Characterization of P1: HPLC (tR 14.03 
min, from 10 to 50% MeCN over 30 min, purity >99%), ESI-MS (m/z calcd. for C37H57N11O11 831.5, 
found 832.6 [M+H]+, 854.5 [M+Na]+, 870.3 [M+K]+
 
). 
In vitro inhibition of integrin – extracellular matrix (ECM) protein binding. The inhibiting activity and 
integrin selectivity of the integrin antagonists were determined in a solid-phase binding assay based 
on previously reported methods with some modifications.[10, 11] Human integrins αvβ3 and αvβ5 were 
purchased from Chemicon Corporation/Millipore, α5β1 from R&D Systems and αIIbβ3 from Enzyme 
Research Laboratories. Vitronectin was purchased from Chemicon Corporation/Millipore, fibronectin 
from Sigma and fibrinogen from Calbiochem. For the integrins α5β1 and αIIbβ3 the binding was 
visualized using antibodies from BD Biosciences (mouse anti-human CD49e for α5β1 and mouse anti-
human CD41b for αIIbβ3) and Sigma (anti-mouse IgG-peroxidase). Peroxidase development was 
performed using the substrate solution 3,3,5,5’-tetramethylethylenediamine (TMB from Seramun 
Diagnostic GmbH) and 3 M H2SO4 for stopping the reaction. Alternatively, for the integrins αvβ3 and 
αvβ5 the binding was detected using the conjugate neutravidin-horseradish peroxidase (HRP) from 
Pierce and the HRP substrate o-phenylenediamine hydrochloride (OPD) from Sigma. The absorbance 
(450, 492 nm) was recorded with a POLARstar Galaxy plate reader (BMG Labtechnologies). Every 
concentration was analyzed by duplicate and the resulting inhibition curves were analyzed using 
OriginPro 7.5G software, the turning point describes the IC50 value. Each plate contained either 
cilengitide or tirofiban as internal controls.[12, 13] Blocking and binding steps were always performed 
with TS buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, and 1 mM MnCl2) 
containing 1% BSA (TSB-buffer). Washings after each incubation step were done with PBST buffer (10 
mM Na2HPO4
Vitronectin-α
 pH 7.5, 150 mM NaCl, and 0.01% Tween 20).  
vβ3 assay. Flat-bottom 96-well ELISA plates (Brand) were coated overnight at room 
temperature with 100 μL/well of 0.4 μg mL-1 human αvβ3 in TS buffer. After emptying the plate the 
wells were blocked for 2 h at 30 °C with 150 μL/well of TSB. Plates were then washed three times 
with 200 μL/well of PBST. Next, test compounds and cilengitide (Orpegen Pharma) as internal control 
(0.0003-10 μM) were mixed with 1 μg mL-1 of human vitronectin, which had been biotinylated with 
sulfo-NHS-LC-LC-biotin (Pierce, 20:1 molar ratio), and 100 μL/well of these solutions were incubated 
for 2 h at 30 °C. After washing the plates five times, 100 μL/well of 0.25 μg mL-1 of neutravidin-HRP 
were added to the plate and incubated for 1 h at 30 °C. After another 5-fold wash, the plate was 
developed by adding 100 μL/well of OPD solution, obtained from dissolving substrate tablets in 
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buffer (24 mM sodium citrate, 50 mM Na2HPO4 pH 5.0, 0.012% H2O2). After 15 min the reaction was 
quenched with 3 M H2SO4
Vitronectin-α
 and the binding analyzed at 492 nm as described above. 
vβ5 assay. The assay is similar to the vitronectin-αvβ3 assay. In brief, flat-bottom 96-
well ELISA plates were coated overnight at room temperature with 100 μL/well of 1.0 μg mL-1 human 
αvβ5 in TS buffer. After blocking and washing the plates, test compounds and cilengitide were mixed 
with 1 µg mL-1 of human biotinylated-vitronectin and were incubated for 2 h at 30 °C. The binding 
was visualized by incubation with neutravidin-HRP and further oxidation of the OPD substrate. IC50
Fibronectin-α
 
values were calculated as previously described. 
5β1 assay. Flat-bottom 96-well ELISA plates were coated overnight at 4 °C with 100 
µL/well of 0.50 μg mL-1 of fibronectin in 15 mM of Na2CO3, 35 mM NaHCO3, pH 9.6 (carbonate 
buffer). Plates were subsequently blocked for 1 h at room temperature. Next, 1.0 µg mL-1 of soluble 
integrin α5β1 and a serial dilution of integrin inhibitors and the control cilengitide were incubated in 
the coated wells for 1 h at room temperature. After washing three times, the plate was treated with 
100 μL/well of primary antibody (CD49e) at 1.0 μg mL-1 (1:500 dilution) and secondary antibody (anti-
mouse IgG-peroxidase) at 2.0 μg mL-1 (1:385 dilution) for 1 h each at room temperature. After this 
treatment the plate was washed three times and the binding visualized with TMB. For this substrate 
the oxidation was left for only 5 min and the absorbance measured at 450 nm. IC50
Fibrinogen-α
 determination 
was done as explained above.  
IIbβ3 assay. The assay is similar to the fibronectin-α5β1 assay. In this case, flat-bottom 
96-well ELISA plates were coated overnight at 4 °C with 100 µL/well of 10.0 μg mL-1 of fibrinogen in 
carbonate buffer. After blocking the plates, 2.5 µg mL-1 of soluble integrin αIIbβ3 and a serial dilution 
of integrin inhibitors and the control molecules cilengitide and tirofiban were incubated in the coated 
wells for 1 h at room temperature. The plate was then washed three times and subsequently treated 
with 100 μL/well of primary antibody (CD41b) at 2.0 μg mL-1 (1:250 dilution) and secondary antibody 
(anti-mouse IgG-peroxidase) at 1.0 μg mL-1 (1:770 dilution) for 1 h each at room temperature. The 
binding was visualized as explained for α5β1.
 
  
Analysis of the antibacterial activity of MccJ25 RGD. The antibacterial acitivity of MccJ25 RGD was 
analyzed in comparison to MccJ25 by a radial diffusion assay against E. coli K12 MC4100. A bacteria 
soft agar layer was prepared by inoculating 10 mL LB soft agar medium (6.5 g L-1 agar) with 100 – 
250 µL inoculum of an E. coli K12 MC4100 culture in the exponential growth phase to reach 107 cfu 
mL-1. The bacterial suspension was deposited onto a 20 mL LB agar layer (15 g L-1
 
 agar) in petri dishes. 
After solidification, 1 nmol MccJ25 and 1 – 10 nmol MccJ25 RGD diluted in Milli-Q water were laid 
over the bacterial layer. Plates were analyzed for the presence of inhibition halos after incubation for 
16 h at 37 °C.  
Analysis of the influence of MccJ25 RGD on capillary formation. Inhibition of capillary formation was 
tested in vitro using human umbilical vein endothelial cells (HUVEC) from LONZA. Frozen Matrigel (BD 
Biosciences) was thawed at -4 °C overnight, and after mixing it with an equal volume of cold EBM-2 
medium (LONZA), 35 µL aliquots were distributed in wells of a 96-well plate placed on ice. The plates 
were kept at 37 °C then for 1 h to let the Matrigel solidify. 25 µL of a suspension of HUVECs (8 x 105 
mL-1) that were harvested from a grown flask by trypsinization were given to each well, to which 
serial dilutions of the compounds were added. Plates were incubated at 37 °C and 10% CO2 
overnight. Tube formation was judged and minimal effective concentrations were estimated by 
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visual inspection under the microscope with a 5 x lens and documented using an attached CCD 
camera.  
 
Proliferation inhibition studies. 60 µL of serial dilutions of the test compounds were added to 120 µL 
aliquots of a cell suspension of HUVECs (50.000 mL-1) in 96-well plates and incubated at 37 °C and 
10% CO2 for 5 d. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was used to 
measure growth and viability of cells which are capable of reducing it to a violet formazan product. 
20 µL MTT in phosphate buffered saline (PBS) were added to a final concentration of 0.5 mg mL-1
 
. 
After 2 h the precipitate of formazan crystals was centrifuged, and the supernatant discarded. The 
precipitate was washed with 100 µL PBS and dissolved in 100 µL isopropanol containing 0.4% 
hydrochloric acid. The microplates were measured at 590 nm using an ELISA plate reader. All 
experiments were carried out in two parallels; the percentage of metabolic activity per well was 
calculated as the mean with respect to the controls set to 100%. 
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Supplementary Results 
 
MS2 fragmentation studies and carboxypeptidase Y digestion of MccJ25 RGD. To confirm the lasso 
structure of the MccJ25 RGD variant, gas phase fragmentation studies were performed in 
comparison to the wild type lasso peptide. MS2 fragmentation of MccJ25 yields in addition to the b 
and y fragment ions, which originate from peptide bond cleavages within the threading tail, binary 
peptide complex fragment ions composed of b and y ions (Supplementary Figure 3, Supplementary 
Table 1). These b+y fragment ions are characteristic for the lasso structure of MccJ25 and result from 
the stable trapping of the tail by Phe19 and Tyr20 located on opposite sides of the macrolactam ring 
(Supplementary Figure 4).[14]
 
 In comparison, the tandem mass spectrometric fragmentation spectrum 
of MccJ25 RGD shows b and y fragment ions consistent with the mass shift resulting from the RGD 
substitution as well as the prototypical binary peptide complex fragment ions (Supplementary Figure 
5, Supplementary Table 2). This fragmentation behavior in combination with the insensitivity towards 
carboxypeptidase Y (Supplementary Figure 6) proves unequivocally the lasso structure of MccJ25 
RGD.  
Structure determination of MccJ25 RGD. Assignments were obtained by standard procedures.[15] A 
combination of DQF-COSY (Supplementary Figure 15) and NOESY (Supplementary Figure 16) 
produced sequential assignments (i.e. all αH and NH and their sequence in the backbone), and a 
combination of DQF-COSY and TOCSY (Supplementary Figure 17) resulted in assignments of the side 
chains (Supplementary Table 5). Structure calculations were performed with the program CYANA 
2.1.[16] The internal linkage was realized by putting a distance constraint between N of Gly1 and Cδ of 
Glu8 to be 1.33 Å. NOE cross-peaks of 100 ms NOESY spectrum were converted into distance 
constraints manually. In this way, 128 distance constraints were obtained, with 53 for backbone, 71 
for long-range, and 75 are for the side-chains (Supplementary Table 3). Thus there were average 7.0 
distance constraints per residue. Torsion angles φ were restrained to -120° ± 30° for Ala3, His5, Val6, 
Glu8, Phe10, Val11, Arg12, Asp14, Ile17, Ser18, Phe19, and Tyr20 with 3JHHα ≥ 8 Hz (Supplementary Table 6). 
The conformation and the range of the corresponding side chain torsion angle χ1 were established 
using standard methods, shown as follows: His5 (t2g3), Tyr9 (g2g3), Phe10 (t2g3), Asp14 (g2t3), and Ser18 
(g2g3).[17] For t2g3, g2t3, and g2g3 conformations around the Cα-Cβ bond, the torsion angle χ1
The above mentioned constraints were used in the simulated annealing protocol for CYANA 2.1 
calculation. The calculation initiated with 200 random conformers and the resultant structures were 
engineered by the program package Sybyl 7.3 to include the covalent linkage between the nitrogen 
of Gly
 was 
constrained in the range of -60 ± 30°, 150 ± 30°, and 60 ± 30°, respectively. 
1 and Cδ of Glu8, followed by energy minimization under NMR constraints using TRIPOS force 
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field within Sybyl 7.3. Thus, on the basis of low energies and minimal violations of the experimental 
data, a family of 20 structures was chosen. These 20 energy-minimized conformers show an average 
root-mean-square deviation (RMSD) for the backbone of 0.2 Å and are kept to represent the solution 
structure of the grafted lasso peptide (Supplementary Table 3). The quality of these structures was 
evaluated using the program PROCHECK.[18]
 
 The structure has been deposited to the Biological 
Magnetic Resonance Bank (BMRB) (accession number: 21000).  
NMR spectroscopic analysis of MccJ25 and MccJ25 RGD. Hydrogen exchange studies of MccJ25 and 
MccJ25 RGD in CD3OD revealed an identical behavior, since the amide hydrogens of Glu8, Phe19 and 
Tyr20 did not exchange after 4 weeks incubation in deuterated solvent indicating strong hydrogen 
bonding (Supplementary Figure 13 and 14). In addition, the 1
 
H chemical shifts of MccJ25 and MccJ25 
RGD show almost no differences (Supplementary Figure 18, Supplementary Table 4 and 5). Thus, the 
installation of the RGD epitope did not significantly alter the overall structure of the molecular 
scaffold. 
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Supplementary Figures 
 
 
Supplementary Figure 1: Insertion site of the integrin binding epitope RGD within the lasso peptide 
scaffold of MccJ25. (A) NMR structure of MccJ25 shown as sticks.[14]
 
 The isopeptide bond between 
Gly1 and Glu8 (red) results in an 8-residue macrolactam ring (yellow) through which the linear C-
terminal tail (blue) is threaded. The Gly12-Ile13-Gly14 sequence (green) located within the turn motif 
of the threading tail was chosen as insertion site for the grafting of the RGD epitope. (B) Primary 
structures of MccJ25 and of the grafted lasso peptide MccJ25 RGD. The GIG sequence to be 
substituted is highlighted in green and the RGD sequence to be grafted in red. 
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Supplementary Figure 2: Preparative purification of MccJ25 RGD. UV chromatogram of a 
preparative RP-HPLC purification of MccJ25 RGD. The microcin J25 variant shows a retention time of 
28.7 min. The ESI-FT-MS spectrum matches the calculated m/z ([M + 2H]2+calculated = 1104.5298; 
[M + 2H]2+observed
 
 = 1104.5314; deviation 1.4 ppm). 
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Supplementary Figure 3: Tandem mass spectrometric studies of MccJ25. MS2 spectrum of the m/z 
1054 doubly protonated species of MccJ25. Red peaks correspond to the b and y fragment ions 
depicted in Supplementary Table 1, whereas blue peaks originate from an additional loss of water. 
Peaks representing sterically linked b+y fragment ions are shown in green. By way of illustration, the 
sterically linked b13+y4
 
 fragment ion (m/z 1739.2) is depicted schematically. 
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Supplementary Figure 4: Steric trapping of the linear C-terminal tail within the N-terminal 
macrolactam ring. (A) NMR structure of MccJ25.[14]
  
 Backbone is shown as cartoon and the side chains 
are depicted as sticks using element specific coloring (C: grey; O: red; N: blue). The surface of Phe19 
and Tyr20 are shown in transparent grey. (B) Solvent accessible surface of the N-terminal 
macrolactam ring is additionally shown in transparent blue. 
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Supplementary Figure 5: Tandem mass spectrometric studies of MccJ25 RGD. MS2 spectrum of the 
m/z 1104.5 doubly protonated species of MccJ25 RGD. Red peaks correspond to the b and y 
fragment ions depicted in Supplementary Table 2, whereas blue peaks originate from an additional 
loss of water. Peaks representing sterically linked b+y fragment ions are shown in green. By way of 
illustration, the sterically linked b14+y4
 
 fragment ion (m/z 1897.0) is depicted schematically. 
  
14 
 
 
 
Supplementary Figure 6: Stability of MccJ25 RGD against carboxypeptidase Y digestion. Incubation 
of MccJ25 RGD in the presence of 1 U carboxypeptidase Y for 2 h at 25 °C does not lead to a 
degradation of the peptide proving its insensitivity towards carboxyterminal degradation which is 
consistent with a lasso structure. 
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Supplementary Figure 7: ELISA based in vitro inhibition of protein-protein binding - αvβ3-
vitronectin assay. Data points are shown for MccJ25 (red triangles), peptide P1 (blue squares) and 
MccJ25 RGD (black circles). The fit is presented as colored line and was obtained using Origin 
(sigmoidal fit). IC50
 
 values derived from the sigmoidal fit are presented in the figure. 
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Supplementary Figure 8: ELISA based in vitro inhibition of protein-protein binding - αvβ5-
vitronectin assay. Data points are shown for MccJ25 (red triangles), peptide P1 (blue squares) and 
MccJ25 RGD (black circles). The fit is presented as colored line and was obtained using Origin 
(sigmoidal fit). IC50
 
 values derived from the sigmoidal fit are presented in the figure. 
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Supplementary Figure 9: ELISA based in vitro inhibition of protein-protein binding – α5β1-
fibronectin assay. Data points are shown for MccJ25 (red triangles), peptide P1 (blue squares) and 
MccJ25 RGD (black circles). The fit is presented as colored line and was obtained using Origin 
(sigmoidal fit). IC50
 
 values derived from the sigmoidal fit are presented in the figure. 
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Supplementary Figure 10: ELISA based in vitro inhibition of protein-protein binding – αIIbβ3-
fibrinogen assay. Data points are shown for MccJ25 (red triangles), peptide P1 (blue squares) and 
MccJ25 RGD (black circles). The fit is presented as colored line and was obtained using Origin 
(sigmoidal fit). IC50
 
 values derived from the sigmoidal fit are presented in the figure. For MccJ25 
neither a sigmoidal nor a linear fitting were possible.  
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Supplementary Figure 11: Stability of the grafted lasso peptide MccJ25 RGD in human serum in 
comparison to the linear peptide P1. The relative amounts of MccJ25 RGD (green squares) and of 
the peptide P1 (red triangles) are plotted versus time. 
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Supplementary Figure 12: Analysis of the antibacterial activity of MccJ25 RGD in comparison to 
MccJ25 by a radial diffusion assay. Shown is the inhibitory effect of 1 nmol Mccj25 and 10 nmol 
MccJ25 RGD towards the growth of Escherichia coli K12 MC4100. 
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Supplementary Figure 13: 1H variable delay spectra in NH region of MccJ25 in CD3
 
OD at 298 K. 
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Supplementary Figure 14: 1H variable delay spectra in NH region of MccJ25 RGD in CD3
  
OD at 298 K. 
23 
 
 
Supplementary Figure 15: Fingerprint region of the DQF-COSY spectrum of MccJ25 RGD in CD3
  
OH 
at 298 K. 
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Supplementary Figure 16: Section of the NOESY spectrum of MccJ25 RGD in CD3
  
OH at 298 K. NOESY 
mixing time was 250 ms. 
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Supplementary Figure 17: Section of the TOCSY spectrum of MccJ25 RGD in CD3OH at 298 K. TOCSY 
mixing time was 80 ms. 
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Supplementary Figure 18: Differences in the chemical shifts of NH (A) and Hα (B) between MccJ25 
and MccJ25 RGD. 
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Supplementary Tables 
 
Supplementary Table 1: Experimental fragmentation series of MccJ25. Peptide sequences 
corresponding to the fragment ions are highlighted. 
 
Fragment ion  [M + H]+ [M + H]calculated 
+
observed 
C-terminal y-series      
GGAGHVPEYFVGIGTPISFYG y 1110.6 11  1110.8  
GGAGHVPEYFVGIGTPISFYG y 841.4 8  841.4  
GGAGHVPEYFVGIGTPISFYG y 784.4 7  784.6  
GGAGHVPEYFVGIGTPISFYG y 683.3 6  683.5  
GGAGHVPEYFVGIGTPISFYG y 586.3 5  586.3  
GGAGHVPEYFVGIGTPISFYG y 473.2 4  473.3  
GGAGHVPEYFVGIGTPISFYG y 386.2 3  386.3  
N-terminal b- and a-series (-H2  O)     
GGAGHVPEYFVGIGTPISFYG b 1424.7 15  1424.8  
GGAGHVPEYFVGIGTPISFYG b 1323.6 14  1323.5  
GGAGHVPEYFVGIGTPISFYG b 1266.7 13  1267.0  
GGAGHVPEYFVGIGTPISFYG b 1153.6 12  1153.8  
GGAGHVPEYFVGIGTPISFYG b 1096.5 11  1096.7  
GGAGHVPEYFVGIGTPISFYG b 997.5 10  997.7  
GGAGHVPEYFVGIGTPISFYG b 850.4 9  850.3  
GGAGHVPEYFVGIGTPISFYG a 659.3 8  659.6  
Sterically linked b+y-series      
GGAGHVPEYFVGIGT(PI)SFYG b15+y 1896.9 4  1897.1  
GGAGHVPEYFVGI(GTPI)SFYG b13+y 1738.8 4  1739.2  
GGAGHVPEYFVG(IGTPI)SFYG b12+y 1625.7 4  1625.8  
GGAGHVPEYFV(GIGTPI)SFYG b11+y 1568.7 4  1568.9  
GGAGHVPEYF(VGIGTPI)SFYG b10+y 1469.7 4  1469.8  
GGAGHVPEY(FVGIGTPI)SFYG b9+y 1322.6 4  1322.9  
GGAGHVPEYFV(GIGT)PISFYG b11+y 1778.9 6  1779.2  
GGAGHVPEYF(VGIGT)PISFYG b10+y 1679.8 6  1680.0  
GGAGHVPEY(FVGIGTP)ISFYG b9+y 1532.7 6  1532.9  
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Supplementary Table 2: Experimental fragmentation series of MccJ25 RGD. Peptide sequences 
corresponding to the fragment ions are highlighted. 
 
Fragment ion  [M + H]+ [M + H]calculated 
+
observed 
C-terminal y-series      
GGAGHVPEYFVRGDTPISFYG y 1358.7 12  1359.0  
GGAGHVPEYFVRGDTPISFYG y 1211.6 11  1211.9  
GGAGHVPEYFVRGDTPISFYG y 1112.5 10  1112.7  
GGAGHVPEYFVRGDTPISFYG y 784.4 7  784.7  
GGAGHVPEYFVRGDTPISFYG y 683.3 6  683.6  
GGAGHVPEYFVRGDTPISFYG y 473.2 4  473.2  
GGAGHVPEYFVRGDTPISFYG y 386.2 3  386.4  
N-terminal b- und a-series (-H2  O)     
GGAGHVPEYFVRGDTPISFYG b 1525.7 15  1526.0  
GGAGHVPEYFVRGDTPISFYG b 1424.7 14  1424.9  
GGAGHVPEYFVRGDTPISFYG b 1309.6 13  1310.0  
GGAGHVPEYFVRGDTPISFYG b 1252.6 12  1252.9  
GGAGHVPEYFVRGDTPISFYG b 1096.5 11  1096.2  
GGAGHVPEYFVRGDTPISFYG b 997.5 10  997.8  
GGAGHVPEYFVRGDTPISFYG b 850.4 9  850.6  
GGAGHVPEYFVRGDTPISFYG a 659.3 8  659.2  
Sterically linked b+y-series      
GGAGHVPEYFVRGD(TPI)SFYG b14+y 1896.9 4  1897.0  
GGAGHVPEYFV(RGDTPI)SFYG b11+y 1568.7 4  1568.9  
GGAGHVPEYF(VRGDTPI)SFYG b10+y 1469.6 4  1469.8  
GGAGHVPEY(FVRGDTPI)SFYG b9+y 1322.6 4  1322.8  
GGAGHVPE(YFVRGDTPI)SFYG b8+y 1159.5 4  1159.7  
GGAGHVPEYFV(RGDT)PISFYG b11+y 1778.9 6  1779.1  
GGAGHVPEYF(VRGDT)PISFYG b10+y 1679.8 6  1680.0  
GGAGHVPEY(FVRGDT)PISFYG b9+y 1532.7 6  1532.9  
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Supplementary Table 3: Structural statistics for the family of 20 structures selected to represent 
the solution structure of MccJ25 RGD. 
 
Restraining Constraints Constraint Violations 
Total: 128 Distance Violations, >0.5 Å: 0 
Distance, i=j: 4 RMS Deviations: 0.021 Å 
Distance, Ii-jI=1: 53 Dihedral Violations, > 5°: 0 
Distance, Ii-jI>1: 71 RMS Deviation: 1.9° 
Dihedral: 19 Average pairwise RMS Deviation (Gly2-Tyr20
Hydrogen Bond: 0 
) 
Backbone Atoms: 0.20 Å 
Constraints/Residue: 7.0 All heavy Atoms: 0.80 Å 
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Supplementary Table 4: 1H chemical shifts of MccJ25 in CD3OH at 298 K.
[19]
 
 
amino acid NH Hα Hβ others 
Gly1  7.960 4.32 
3.54 
  
Gly2 9.015 4.22 
3.89 
  
Ala3 8.562 4.68 1.306  
Gly4 7.773 4.06 
3.53 
  
His5 7.600 4.63 3.30 
2.93 
 
Val6 8.848 4.70 1.79 γCH3: 1.099; 0.855 
Pro7  4.23 pro-S 1.80 
pro-R 1.70 
pro-S γ 2.25; pro-R γ 2.02 
pro-R δ 4.14; pro-S δ 3.83 
Glu8 8.362 4.40 1.74 
1.65 
γCH2: 2.00; 1.90 
Tyr9 7.350 4.56 2.88 
2.66 
H2,6: 6.94; H3,5: 6.59 
Phe10 8.307 4.86 
 
2.95 
2.77 
H2,6: 7.06; H3,5
H
: 7.15 
4: 7.07 
Val11 8.277 4.30 2.14 γCH3: 0.945; 0.912 
Gly12 8.160 4.00 
3.75 
  
Ile13 8.329 4.16 1.95 γCH2
γCH
: 1.55; 1.21 
3
δCH
: 0.932 
3: 0.889 
Gly14 8.456 4.06 
3.63 
1.907 
1.566 
 
Thr15 7.911 4.75 4.12 γCH3: 1.210 
Pro16  4.50 pro-S 1.85 
pro-R 1.74 
pro-S γ 2.17; pro-R γ 1.98 
pro-R δ 4.03; pro-S δ 3.85 
Ile17 7.986 4.44 1.87 γCH2
γCH
: 1.43; 1.08 
3
δCH
: 0.847 
3: 0.851 
Ser18 7.365 4.40 4.10 
3.86 
 
Phe19 8.902 5.46 2.60 
2.60 
H2,6: 6.87; H3,5
H
: 7.15 
4: 7.07 
Tyr20 9.523 4.94 3.02 
3.02 
H2,6: 6.95; H3,5: 6.70 
Gly21 8.594 3.80 
3.76 
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Supplementary Table 5: 1H chemical shifts of MccJ25 RGD in CD3
 
OH at 298 K. 
amino acid NH Hα Hβ others 
Gly1  7.873 4.200 
3.566 
  
Gly2 9.034 4.232 
3.856 
  
Ala3 8.511 4.658 1.312  
Gly4 7.761 4.050 
3.484 
  
His5 7.381 4.694 3.245 
2.962 
H2: 8.706; H4: 7.340 
Val6 8.682 4.690 1.76 γCH3: 1.114; 0.852 
Pro7  4.278 1.878 
1.676 
γCH2
δCH
: 2.209; 1.965 
2: 4.124; 3.796 
Glu8 8.263 4.330 1.755 
1.652 
γCH2: 1.997; 1.852 
Tyr9 7.562 4.479 2.897 
2.690 
H2,6: 6.92; H3,5: 6.614 
Phe10 8.043 4.707 2.972 
2.819 
H2,6: 7.075; H3,5: 7.184 
Val11 8.071 4.181 2.030 γCH3: 0.915; 0.909 
Arg12 8.262 4.170 1.851 
1.769 
γCH2
δCH
: 1.651 
2
NH: 7.418 
: 3.217 
Gly13 8.526 4.000 
3.645 
  
Asp14 8.392 4.759 2.874 
2.808 
 
Thr15 7.965 4.761 4.182 1.242 
Pro16  4.461 1.998 
1.805 
γCH2
δCH
: 2.097; 1.991 
2: 3.936; 3.848 
Ile17 7.858 4.357 1.840 γCH3
γCH
: 0.823 
2
δCH
: 1.413 
3: 1.056 
Ser18 7.417 4.381 3.994 
3.829 
 
Phe19 8.815 5.447 2.575 
2.554 
H2,6: 6.868; H3,5: 7.085 
Tyr20 9.493 4.918 3.024 
2.977 
H2,6: 6.966; H3,5: 6.707 
Gly21 8.627 3.853   
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Supplementary Table 6: J coupling constants of MccJ25 RGD in CD3
 
OH at 298 K. 
amino acid peak positions  assignment  J (Hz) 
Gly1 7.873-4.200 3J 8.5 HHA3 
Gly1 7.873-3.566 3J 5.7 HHA2 
Gly1 4.2000-3.566 2J 18.5 HA2HA3 
Gly2 9.034-4.232 3J 7.2 HHA3 
Gly2 9.034-3.856 3J 4.6 HHA3 
Gly2 4.232-3.856 2J 16.8 HA2HA3 
Ala3 8.511-4.658 3J 8.6 HHA 
Ala3 4.658-1.312 3J 7.3 HAHB 
Gly4 7.761-4.050 3J 8.2 HHA3 
Gly4 7.761-3.484 3J 4.6 HHA2 
Gly4 4.050-3.484 2J 18.5 HA2HA3 
His5 7.389-4.701 3J 10.1 HHA 
His5 4.701-3.244 3J 3.5 HAHB2 
His5 4.701-2.916 3J 6.1 HAHB3 
His5 3.324-2.916 2J 16.1 HB2HB3 
Val6 8.682-4.690 3J 8.9 HHA 
Val6 4.690-1.760 3J not observed HAHB 
Val6 1.760-1.114 3J 8.2 HBHG1 
Val6 1.760-0.852 3J 7.9 HBHG2 
Glu8 8.263-4.330 3J 9.1 HHA 
Tyr9 7.562-4.479 3J not observed HHA 
Tyr9 4.479-2.897 3J 7.0 HAHB3 
Tyr9 4.479-2.690 3J 5.0 HAHB2 
Phe10 8.043-4.707 3J 9.0 HHA 
Phe10 4.707-2.972 3J 5.7 HAHB2 
Phe10 4.707-2.819 3J 5.1 HAHB3 
Val11 8.071-4.181 3J 9.5 HHA 
Val11 4.181-2.030 3J not observed HAHB 
Arg12 8.262-4.170 3J 8.2 HHA 
Gly13 8.526-4.000 3J 6.9 HHA3 
Gly13 8.526-3.645 3J 5.7 HHA2 
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amino acid peak positions  assignment  J (Hz) 
Gly13 4.000-3.645 2J 17.3 HA2HA3 
Asp14 8.392-4.759 3J 8.7 HHA 
Asp14 4.759-2.874 3J 5.1 HAHB2 
Asp14 4.759-2.808 3J 6.0 HAHB3 
Thr15 7.965-4.761 3J 7.9 HHA 
Thr15 4.182-1.242 3J 7.2 HBHG2 
Ile17 7.858-4.357 3J 9.7 HHA 
Ser18 7.417-4.381 3J 8.8 HHA 
Ser18 4.381-3.994 3J 5.52 HAHB2 
Ser18 4.381-3.829 3J 5.03 HAHB3 
Phe19 8.815-5.447 3J 10.8 HHA 
Phe19 5.447-2.575 3J not observed HAHB3 
Phe19 5.447-2.554 3J not observed HAHB2 
Tyr20 9.493-4.918 3J 8.1 HHA 
Tyr20 4.918-3.024 3J not observed HAHB2 
Tyr20 4.918-2.977 3J not observed HAHB3 
Gly21 8.627-3.853 3J 6.5 HHA 
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